-
ABOUT USSSY Group Limited is a large high-tech pharmaceutical enterprise with coordinated development of R&D and industrialization in multiple fields such as new drugs, generic drugs, characteristic APIs
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the development mode of “production, learning, research, and application” of multi-disciplinary integration and multi-directional combination.
-
RECRUITIt has established high-level innovation platforms such as engineering laboratory and technology research center jointly with Chinese Academy of Sciences, and now has nearly 400 high-level talents in drug research, analysis and clinical research.
-
SUBSIDIARIESThe company has a diversified business development pattern of R&D, production and export of new drugs, generic drugs, characteristic APIs, advanced finished pharmaceutical products, biological preparations and pharmaceutical packaging materials.
-
CONTACTWe will continue to strengthen innovation-driven development, will vigorously encourage the integration of production and research, strengthen and improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs
Shijiazhuang Sihua Pharmaceutical Group’s New Product, Cinacalcet Hydrochloride Tablets, Approved
Category:
发布时间：2023-05-17
【概要描述】
On May 17, Shijiazhuang Sihua Pharmaceutical Group’s Class 4 chemical drug application for Cinacalcet Hydrochloride Tablets (25 mg) received approval for drug manufacturing registration from the National Medical Products Administration and is deemed to have passed the bioequivalence evaluation.
On May 17, Shijiazhuang Sihua Pharmaceutical Group’s Class 4 chemical drug application for Cinacalcet Hydrochloride Tablets (25 mg) received approval for drug manufacturing registration from the National Medical Products Administration and is deemed to have passed the bioequivalence evaluation.
According to reports, cinacalcet hydrochloride tablets are primarily indicated for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease (CKD) undergoing maintenance dialysis.
Over the past two years, Shijiazhuang Sihua Pharmaceutical has been driven by innovation to promote high-quality enterprise development, bringing its R&D and innovation efforts into a period of concentrated成果. To date this year, the company has launched 27 new products, with R&D efficiency ranking among the top in the national industry; it is projected that more than 80 new products will receive approval for the full year.
Meanwhile, the cumulative number of generic drugs that have passed the quality and therapeutic equivalence evaluation (or are deemed to have passed such evaluation) has reached 47 varieties encompassing 61 specifications, continuously injecting new momentum into enterprises’ high-quality development.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com
Mobile site
E code
Non-Commercial (Filing) – 2025-0091